{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:38:06Z","timestamp":1771663086341,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1136\/ard.2005.042945","type":"journal-article","created":{"date-parts":[[2005,7,14]],"date-time":"2005-07-14T00:14:23Z","timestamp":1121300063000},"page":"1523-1524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Refractory adult onset Still's disease and hypersensitivity to non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors: are biological agents the solution?"],"prefix":"10.1016","volume":"64","author":[{"given":"E H J G","family":"Aarntzen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P L C M","family":"van Riel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Barrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2005.042945_bib1","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/art.10231","article-title":"Etanercept in the treatment of adult patients with Still's disease","volume":"46","author":"Husni","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.042945_bib2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/ard.2004.024026","article-title":"Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases","volume":"64","author":"Fautrel","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2005.042945_bib3","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/ard.2004.026617","article-title":"Refractory adult onset Still's disease successfully treated with anakinra","volume":"64","author":"Vasques","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2005.042945_bib4","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1345\/aph.1C497","article-title":"Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity","volume":"37","author":"West","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1136\/ard.2005.042945_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1067\/mai.2001.116290","article-title":"Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma","volume":"108","author":"Stevenson","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1136\/ard.2005.042945_bib6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1385\/CRIAI:24:2:137","article-title":"Anaphylactic and anaphylactoid reactions to aspirin and other NSAIDs","volume":"24","author":"Berkes","year":"2003","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1136\/ard.2005.042945_bib7","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.10885","article-title":"Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type","volume":"48","author":"Quartier","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.042945_bib8","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1136\/ard.2003.014886","article-title":"The German etanercept registry for treatment of juvenile idiopathic arthritis","volume":"63","author":"Horneff","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2005.042945_bib9","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"201","author":"Pascual","year":"2005","journal-title":"J Exp Med"},{"key":"10.1136\/ard.2005.042945_bib10","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1084\/jem.20050640","article-title":"Blocking IL-1 in systemic inflammation","volume":"201","author":"Dinarello","year":"2005","journal-title":"J Exp Med"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724428392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724428392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2005.042945","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T07:53:57Z","timestamp":1737359637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724428392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S0003496724428392"],"URL":"https:\/\/doi.org\/10.1136\/ard.2005.042945","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Refractory adult onset Still's disease and hypersensitivity to non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors: are biological agents the solution?","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2005.042945","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Copyright 2005 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}